Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTSH for Radioactive Iodine Remnant Ablation in Postoperative Differentiated Thyroid Cancer
NCT04964284Phase 3Completed
- Sponsor
- Zelgen
- Start
- Oct 2021
- Primary completion
- Jan 2026
- Modality
- Biologic, rProtein (Recombinant Protein), Hormone
- Countries
- 1
01
Overview
A Phase 3 trial of thyrotropin alfa in differentiated thyroid cancer (DTC), sponsored by Zelgen. Started Oct 2021; status: completed.
02
Drugs
thyrotropin alfa
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT04964284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04964284.